Dimerix Receives First Development Milestone Payment From Japan Partner

MT Newswires Live

06-30

Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.

DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.

The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.

Shares rose nearly 2% in morning trade Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2547031511"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547031511\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2547031511?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547031511","market":"sh","top_or_hot":-1,"title":"Dimerix Receives First Development Milestone Payment From Japan Partner","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.</p><p>DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.</p><p>Shares rose nearly 2% in morning trade Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Receives First Development Milestone Payment From Japan Partner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Receives First Development Milestone Payment From Japan Partner\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-30 09:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.</p><p>DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.</p><p>Shares rose nearly 2% in morning trade Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治療股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547031511","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547031511","pubTimestamp":1751247381,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.Shares rose nearly 2% in morning trade Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","DXB.AU":"DIMERIX LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Dimerix收到日本合作伙伴的首笔开发里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9},"content_text":"Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.Shares rose nearly 2% in morning trade Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}